{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:11:58Z","timestamp":1790665918173,"version":"4.1.0"},"posted":{"date-parts":[[2023,2,4]]},"group-title":"Cell Biology","reference-count":76,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Cystic fibrosis (CF) is one of the most prevalent lethal genetic diseases with over 2000 identified mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Pharmacological chaperones such as Lumacaftor (VX-809), Tezacaftor (VX-661) and Elexacaftor (VX-445) treat mutation-induced defects by stabilizing CFTR and are called correctors. These correctors improve proper folding and thus facilitate processing and trafficking to increase the amount of functional CFTR on the cell surface. Yet, CFTR variants display differential responses to each corrector. Here, we report variants P67L and L206W respond similarly to VX-809 but divergently to VX-445 with P67L exhibiting little rescue when treated with VX-445. We investigate the underlying cellular mechanisms of how CFTR biogenesis is altered by correctors in these variants. Affinity purification-mass spectrometry (AP-MS) multiplexed with isobaric Tandem Mass Tags (TMT) was used to quantify CFTR protein-protein interaction changes between variants P67L and L206W. VX-445 facilitates unique proteostasis factor interactions especially in translation, folding, and degradation pathways in a CFTR variant-dependent manner. A number of these interacting proteins knocked down by siRNA, such as ribosomal subunit proteins, moderately rescued fully glycosylated P67L. Importantly, these knock-downs sensitize P67L to VX-445 and further enhance the correction of this variant. Our results provide a better understanding of VX-445 biological mechanism of action and reveal cellular targets that may sensitize unresponsive CFTR variants to known and available correctors.<\/jats:p>","DOI":"10.1101\/2023.02.04.527134","type":"posted-content","created":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T00:40:20Z","timestamp":1675557620000},"source":"Crossref","is-referenced-by-count":9,"title":["Elexacaftor\/VX-445-mediated CFTR interactome remodeling reveals differential correction driven by mutation-specific translational dynamics"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9854-2999","authenticated-orcid":false,"given":"Minsoo","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0572-330X","authenticated-orcid":false,"given":"Eli Fritz","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5039-8825","authenticated-orcid":false,"given":"Carleen Mae P.","family":"Sabusap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1357-659X","authenticated-orcid":false,"given":"Bibek","family":"Timalsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disha","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2154-0017","authenticated-orcid":false,"given":"Andras","family":"Rab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9341-3354","authenticated-orcid":false,"given":"Eric J.","family":"Sorscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4363-6116","authenticated-orcid":false,"given":"Lars","family":"Plate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2023020712350560000_2023.02.04.527134v1.1","unstructured":"Cystic Fibrosis Foundation Patient Registry 2021 Annual Data Report. https:\/\/www.cff.org\/media\/23476\/download (2022)."},{"key":"2023020712350560000_2023.02.04.527134v1.2","doi-asserted-by":"crossref","unstructured":"Lopes-Pacheco, M. CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Front. Pharmacol. 10, (2019).","DOI":"10.3389\/fphar.2019.01662"},{"key":"2023020712350560000_2023.02.04.527134v1.3","doi-asserted-by":"publisher","DOI":"10.1126\/science.2475911"},{"key":"2023020712350560000_2023.02.04.527134v1.4","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1055\/s-0039-1694021","article-title":"Cystic Fibrosis: Pathophysiology of Lung Disease","volume":"40","year":"2019","journal-title":"Semin. Respir. Crit. Care Med"},{"key":"2023020712350560000_2023.02.04.527134v1.5","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00031-19"},{"key":"2023020712350560000_2023.02.04.527134v1.6","doi-asserted-by":"publisher","DOI":"10.1177\/0884533615591604"},{"key":"2023020712350560000_2023.02.04.527134v1.7","unstructured":"Cystic Fibrosis Mutation Database-Cystic Fibrosis Genetic Analysis Consortium. http:\/\/www.genet.sickkids.on.ca\/app."},{"key":"2023020712350560000_2023.02.04.527134v1.8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1807120"},{"key":"2023020712350560000_2023.02.04.527134v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2023020712350560000_2023.02.04.527134v1.10","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-200393"},{"key":"2023020712350560000_2023.02.04.527134v1.11","first-page":"4524","article-title":"Full Rescue of F508del-CFTR Processing and Function by CFTR Modulators Can Be Achieved by Removal of Two Regulatory Regions","volume":"21","year":"2020","journal-title":"Int. J. Mol. Sci. 2020, Vol. 21, Page 4524"},{"key":"2023020712350560000_2023.02.04.527134v1.12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1105787108"},{"key":"2023020712350560000_2023.02.04.527134v1.13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24898"},{"key":"2023020712350560000_2023.02.04.527134v1.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra043184"},{"key":"2023020712350560000_2023.02.04.527134v1.15","doi-asserted-by":"publisher","DOI":"10.1124\/mol.118.111799"},{"key":"2023020712350560000_2023.02.04.527134v1.16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/prot.25496","article-title":"Comprehensive mapping of cystic fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding site","volume":"86","year":"2018","journal-title":"Proteins Struct. Funct. Bioinforma"},{"key":"2023020712350560000_2023.02.04.527134v1.17","doi-asserted-by":"publisher","DOI":"10.1124\/mol.117.108373"},{"key":"2023020712350560000_2023.02.04.527134v1.18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2021.12.009","article-title":"Mechanism of CFTR correction by type I folding correctors","volume":"185","year":"2022","journal-title":"Cell"},{"key":"2023020712350560000_2023.02.04.527134v1.19","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1126\/science.ade2216","article-title":"Molecular structures reveal synergistic rescue of \u0394508 CFTR by Trikafta modulators","volume":"378","year":"2022","journal-title":"Science (80-.)"},{"key":"2023020712350560000_2023.02.04.527134v1.20","doi-asserted-by":"crossref","unstructured":"Veit, G. et al. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination. JCI Insight 5, (2020).","DOI":"10.1172\/jci.insight.139983"},{"key":"2023020712350560000_2023.02.04.527134v1.21","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1253"},{"key":"2023020712350560000_2023.02.04.527134v1.22","doi-asserted-by":"crossref","unstructured":"Rotolo, S. M. , Duehlmeyer, S. , Slack, S. M. , Jacobs, H. R. & Heckman, B. Testicular pain following initiation of elexacaftor\/tezacaftor\/ivacaftor in males with cystic fibrosis. J. Cyst. Fibros. (2020) doi:https:\/\/doi.org\/10.1016\/j.jcf.2020.04.017.","DOI":"10.1016\/j.jcf.2020.04.017"},{"key":"2023020712350560000_2023.02.04.527134v1.23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jcf.2021.10.002","article-title":"Mental status changes during elexacaftor\/tezacaftor \/ ivacaftor therapy","volume":"21","year":"2022","journal-title":"J. Cyst. Fibros"},{"key":"2023020712350560000_2023.02.04.527134v1.24","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.177907"},{"key":"2023020712350560000_2023.02.04.527134v1.25","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-020-03540-9"},{"key":"2023020712350560000_2023.02.04.527134v1.26","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1159\/000475578","article-title":"Combination of correctors rescues CFTR transmembrane-domain mutants by mitigating their interactions with proteostasis","volume":"41","year":"2017","journal-title":"Cell. Physiol. Biochem"},{"key":"2023020712350560000_2023.02.04.527134v1.27","doi-asserted-by":"crossref","unstructured":"Needham, P. G. , Guerriero, C. J. & Brodsky, J. L. Chaperoning endoplasmic reticulum\u2013 associated degradation (ERAD) and protein conformational diseases. Cold Spring Harb. Perspect. Biol. 11, (2019).","DOI":"10.1101\/cshperspect.a033928"},{"key":"2023020712350560000_2023.02.04.527134v1.28","doi-asserted-by":"crossref","unstructured":"Estabrooks, S. & Brodsky, J. L. Regulation of CFTR biogenesis by the proteostatic network and pharmacological modulators. Int. J. Mol. Sci. 21, (2020).","DOI":"10.3390\/ijms21020452"},{"key":"2023020712350560000_2023.02.04.527134v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.06.041"},{"key":"2023020712350560000_2023.02.04.527134v1.30","doi-asserted-by":"publisher","DOI":"10.1038\/35050509"},{"key":"2023020712350560000_2023.02.04.527134v1.31","doi-asserted-by":"publisher","DOI":"10.1038\/nature15729"},{"key":"2023020712350560000_2023.02.04.527134v1.32","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1016\/j.jmb.2018.06.017","article-title":"A Proteomic Variant Approach (ProVarA) for Personalized Medicine of Inherited and Somatic Disease","volume":"430","year":"2018","journal-title":"J. Mol. Biol"},{"key":"2023020712350560000_2023.02.04.527134v1.33","doi-asserted-by":"crossref","first-page":"ar62","DOI":"10.1091\/mbc.E21-11-0578","article-title":"Distinct proteostasis states drive pharmacologic chaperone susceptibility for cystic fibrosis transmembrane conductance regulator misfolding mutants","volume":"33","year":"2022","journal-title":"Mol. Biol. Cell"},{"key":"2023020712350560000_2023.02.04.527134v1.34","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90240-6"},{"key":"2023020712350560000_2023.02.04.527134v1.35","doi-asserted-by":"crossref","unstructured":"Han, S. T. et al. Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators. JCI insight 3, (2018).","DOI":"10.1172\/jci.insight.121159"},{"key":"2023020712350560000_2023.02.04.527134v1.36","first-page":"86581","article-title":"Analysis of cystic fibrosis\u2013associated P67L CFTR illustrates barriers to personalized therapeutics for orphan diseases","volume":"1","year":"2016","journal-title":"JCI Insight"},{"key":"2023020712350560000_2023.02.04.527134v1.37","doi-asserted-by":"crossref","unstructured":"Sabusap, C. M. et al. The CFTR P67L variant reveals a key role for N-terminal lasso helices in channel folding, maturation, and pharmacologic rescue. J. Biol. Chem. 296, (2021).","DOI":"10.1016\/j.jbc.2021.100598"},{"key":"2023020712350560000_2023.02.04.527134v1.38","doi-asserted-by":"crossref","first-page":"100008","DOI":"10.1074\/mcp.RA120.002168","article-title":"Thyroglobulin interactome profiling defines altered proteostasis topology associated with thyroid dyshormonogenesis","volume":"20","year":"2021","journal-title":"Mol. Cell. Proteomics"},{"key":"2023020712350560000_2023.02.04.527134v1.39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3009540"},{"key":"2023020712350560000_2023.02.04.527134v1.40","doi-asserted-by":"crossref","unstructured":"Veit, G. et al. A precision medicine approach to optimize modulator therapy for rare cftr folding mutants. J. Pers. Med. 11, (2021).","DOI":"10.3390\/jpm11070643"},{"key":"2023020712350560000_2023.02.04.527134v1.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.03.011"},{"key":"2023020712350560000_2023.02.04.527134v1.42","doi-asserted-by":"crossref","unstructured":"Shaughnessy, C. A. , Zeitlin, P. L. & Bratcher, P. E. Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment. Sci. Rep. 11, (2021).","DOI":"10.1038\/s41598-021-99184-1"},{"key":"2023020712350560000_2023.02.04.527134v1.43","doi-asserted-by":"crossref","first-page":"848","DOI":"10.21037\/tcr.2019.05.05","article-title":"Knockdown of RPL34 suppresses osteosarcoma cell proliferation likely through EIF3\/FAU signaling pathway","volume":"8","year":"2019","journal-title":"Transl. Cancer Res"},{"key":"2023020712350560000_2023.02.04.527134v1.44","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1007\/s12010-022-03857-0","article-title":"Suppression of RPL34 Inhibits Tumor Cell Proliferation and Promotes Apoptosis in Glioblastoma","volume":"194","year":"2022","journal-title":"Appl. Biochem. Biotechnol"},{"key":"2023020712350560000_2023.02.04.527134v1.45","doi-asserted-by":"publisher","DOI":"10.4161\/cc.9.19.13299"},{"key":"2023020712350560000_2023.02.04.527134v1.46","doi-asserted-by":"crossref","unstructured":"Daftuar, L. , Zhu, Y. , Jacq, X. & Prives, C. Ribosomal proteins RPL37, RPS15 and RPS20 regulate the Mdm2-p53-MdmX network. PLoS One 8, (2013).","DOI":"10.1371\/journal.pone.0068667"},{"key":"2023020712350560000_2023.02.04.527134v1.47","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/psp4.12751","article-title":"Translating in vitro CFTR rescue into small molecule correctors for cystic fibrosis using the Library of Integrated Network\u25a1based Cellular Signatures drug discovery platform","volume":"11","year":"2022","journal-title":"CPT Pharmacometrics Syst. Pharmacol"},{"key":"2023020712350560000_2023.02.04.527134v1.48","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.1172\/JCI124282","article-title":"Slowing ribosome velocity restores folding and function of mutant CFTR","volume":"129","year":"2019","journal-title":"J. Clin. Invest"},{"key":"2023020712350560000_2023.02.04.527134v1.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2005.09.007"},{"key":"2023020712350560000_2023.02.04.527134v1.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2011.02.027"},{"key":"2023020712350560000_2023.02.04.527134v1.51","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa3974"},{"key":"2023020712350560000_2023.02.04.527134v1.52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13889-6"},{"key":"2023020712350560000_2023.02.04.527134v1.53","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.003192"},{"key":"2023020712350560000_2023.02.04.527134v1.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2019.12.060"},{"key":"2023020712350560000_2023.02.04.527134v1.55","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjv014"},{"key":"2023020712350560000_2023.02.04.527134v1.56","first-page":"640","article-title":"Structure of the human 80S ribosome","volume":"520","year":"2015","journal-title":"Nat. 2015 5207549"},{"key":"2023020712350560000_2023.02.04.527134v1.57","doi-asserted-by":"publisher","DOI":"10.1096\/fj.07-105338"},{"key":"2023020712350560000_2023.02.04.527134v1.58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210041"},{"key":"2023020712350560000_2023.02.04.527134v1.59","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E04-04-0293"},{"key":"2023020712350560000_2023.02.04.527134v1.60","first-page":"24","article-title":"Rare trafficking cftr mutations involve distinct cellular retention machineries and require different rescuing strategies","volume":"23","year":"2022","journal-title":"Int. J. Mol. Sci"},{"key":"2023020712350560000_2023.02.04.527134v1.61","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M108879200"},{"key":"2023020712350560000_2023.02.04.527134v1.62","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jmgm.2019.04.003","article-title":"Deciphering the three-domain architecture in schlafens and the structures and roles of human schlafen12 and serpinB12 in transcriptional regulation","volume":"90","year":"2019","journal-title":"J. Mol. Graph. Model"},{"key":"2023020712350560000_2023.02.04.527134v1.63","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.14.4970-4978.2000"},{"key":"2023020712350560000_2023.02.04.527134v1.64","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.275"},{"key":"2023020712350560000_2023.02.04.527134v1.65","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3390\/genes6030543","article-title":"Chromatin Dynamics in the Regulation of CFTR Expression","volume":"6","year":"2015","journal-title":"Genes (Basel)"},{"key":"2023020712350560000_2023.02.04.527134v1.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2018.02.001"},{"key":"2023020712350560000_2023.02.04.527134v1.67","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.002607"},{"key":"2023020712350560000_2023.02.04.527134v1.68","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M204196200"},{"key":"2023020712350560000_2023.02.04.527134v1.69","doi-asserted-by":"publisher","DOI":"10.1159\/000343303"},{"key":"2023020712350560000_2023.02.04.527134v1.70","doi-asserted-by":"crossref","unstructured":"H\u00f6hn, A. , Tramutola, A. & Cascella, R. Proteostasis Failure in Neurodegenerative Diseases: Focus on Oxidative Stress. Oxid. Med. Cell. Longev. 2020, (2020).","DOI":"10.1155\/2020\/5497046"},{"key":"2023020712350560000_2023.02.04.527134v1.71","doi-asserted-by":"publisher","DOI":"10.1093\/NAR\/GKAB1038"},{"key":"2023020712350560000_2023.02.04.527134v1.72","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2557"},{"key":"2023020712350560000_2023.02.04.527134v1.73","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1039\/b401644k","article-title":"Transfection of cells with custom-made calcium phosphate nanoparticles coated with DNA","volume":"14","year":"2004","journal-title":"J. Mater. Chem"},{"key":"2023020712350560000_2023.02.04.527134v1.74","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2016.140"},{"key":"2023020712350560000_2023.02.04.527134v1.75","first-page":"38","article-title":"MudPIT: A Powerful Proteomics Tool for Discovery","volume":"2","year":"2009","journal-title":"Discov. Med"},{"key":"2023020712350560000_2023.02.04.527134v1.76","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1021\/acsinfecdis.0c00500","article-title":"Comparative Multiplexed Interactomics of SARS-CoV-2 and Homologous Coronavirus Nonstructural Proteins Identifies Unique and Shared Host-Cell Dependencies","volume":"6","year":"2020","journal-title":"ACS Infect. Dis"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.02.04.527134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:13:59Z","timestamp":1768450439000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2023.02.04.527134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,4]]},"references-count":76,"URL":"https:\/\/doi.org\/10.1101\/2023.02.04.527134","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1016\/j.jbc.2023.105242","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,2,4]]},"subtype":"preprint"}}